Azmiro

Azmiro^® is a prescription medication containing testosterone cypionate, an androgen used for testosterone replacement therapy (TRT) in adult men with low testosterone—sometimes called hypogonadism—caused by certain medical conditions.

The recommended dosage of Azmiro is 50 milligrams (mg) to 400 mg administered every two to four weeks as an intramuscular injection in the gluteal muscle. The specific dose and schedule depends on the person’s age, diagnosis, response to treatment, and whether they have any adverse reactions.

Common side effects of Azmiro include injection site reactions (such as bruising, bleeding, redness, or hardness), increased red blood cell count, enlarged or painful breasts, headache, and depression. Serious side effects may include an increased risk of heart attack or stroke, worsening of benign prostatic hyperplasia (BPH), potential risk of prostate cancer, blood clots in the legs or lungs, liver problems, and breathing problems during sleep (sleep apnea). Discuss the potential risks and benefits with your healthcare provider before starting treatment.

Azmiro (testosterone cypionate) is indicated for:

• Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Androgen

Common adverse reactions (incidence ≥4%) are:

• Injection site redness

• Injection site reaction

Other adverse reactions include:

• Polycythemia

• Enlargement of breast tissue in males

• Headache

• Depression

The price of Azmiro may vary depending on the dosage, quantity, where you buy it, and your insurance plan. The average retail price of Azmiro is about $592 for two 200-mg doses, but coupons and discount cards may be available to bring down the price. Health insurance may cover all or some of the cost of this medication.

The Azmiro Co-Pay Assistance Program allows eligible people to get Azmiro for as little as $0 per month with insurance, while the AzmiroSelect cash program offers access to Azmiro for $110 per month for eligible people who are uninsured or have health insurance that does not cover Azmiro.

There is currently no lower-cost generic version of Azmiro available.

• Known hypersensitivity to Azmiro or any of its components, skin manifestations and anaphylactoid reactions have been reported

• Men with carcinoma of the breast or known or suspected carcinoma of the prostate

• Women who are pregnant. Testosterone may cause fetal harm

• Drug interactions: Insulin, oral anticoagulants, corticosteroids

• Polycythemia

• Cardiovascular risk: Azmiro may increase the risk of major adverse cardiovascular events (MACE)

• Worsening of benign prostatic hyperplasia (BPH) and potential risk of prostate cancer

• Venous thromboembolism (VTE): VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone products

• Abuse of testosterone and monitoring of serum testosterone

• Potential for adverse effects on spermatogenesis

• Edema

• Sleep apnea

• Lipid changes

• Adverse effects on bone maturation

*This information is from the label for brand name Azmiro^®. See the Full Prescribing Information for more complete information. Testosterone cypionate, the active ingredient in Azmiro, may also be the active ingredient in other medications, and this information may not be accurate for all medications that include the active ingredient testosterone cypionate.